Navigation Links
Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
Date:10/27/2011

of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

ADASUVE (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder.  Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009.  In October 2010, the Company received a Complete Response Letter from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011.  The ADASUVE NDA was resubmitted on August 4, 2011 and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.  The ADASUVE NDA will be presented to an advisory committee on December 12, 2011.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer International, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011.  

For mo
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Intarcia Therapeutics, Inc. ... for its lead candidate ITCA 650 (continuous subcutaneous delivery ... baseline HbA1c levels at the 50 th Annual ... Diabetes (EASD). Data from the open-label, phase 3 FREEDOM-HBL ... sugar in patients with poorly controlled type 2 diabetes. ...
(Date:9/19/2014)... September 19, 2014 Reductions in ... many years in people with diabetes type 2 ... term benefits for the kidneys." Australian researchers ... type 2 diabetes leads to persistent reductions in kidney ... The global study has found that, five and ...
(Date:9/18/2014)... 18, 2014  Low T Center endorses the ... Hyattsville, Maryland earlier this ... proper patient population for testosterone therapy (TRT), as ... with TRT. Examining recent claims from studies that TRT ... epidemiological studies do not provide convincing evidence that ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2
... DEERFIELD, IL, June 04, 2007,/PRNewswire-FirstCall/ - Cardiome ... US, Inc. ("Astellas") today,announced results from their ... 2. The trial evaluated the efficacy and ... (iv)") for the treatment of patients who ...
... -- ZymoGenetics,Inc. today announced that interim findings were ... in B-cell chronic,lymphocytic leukemia (B-CLL) at the American ... study included intravenous,administration of higher doses than had ... atacicept was well-tolerated and biologically,active at all dose ...
Cached Medicine Technology:Cardiome And Astellas Announce Positive Results From ACT 2 Trial 2Cardiome And Astellas Announce Positive Results From ACT 2 Trial 3Cardiome And Astellas Announce Positive Results From ACT 2 Trial 4Cardiome And Astellas Announce Positive Results From ACT 2 Trial 5Cardiome And Astellas Announce Positive Results From ACT 2 Trial 6ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 2ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial,in B-Cell Chronic Lymphocytic Leukemia 3
(Date:9/20/2014)... (PRWEB) September 20, 2014 The Arizona ... College (MCC) is celebrating National Manufacturing Day by opening ... enhanced machining, processing and additive manufacturing labs will be ... 3, 2014 at MCC’s Southern and Dobson campus (1833 ... in southeast Lot D. , The AzAMI at MCC ...
(Date:9/20/2014)... Nevada (PRWEB) September 20, 2014 ... extremely successful showing at the PAIN Week conference ... Cosmopolitan Hotel and Casino in Las Vegas from ... MarijuanaDoctors.com primarily attended PAIN Week in the hopes ... as a viable and legitimate tool to treat ...
(Date:9/19/2014)... 20, 2014 Consistent premium price ... the Vision Insurance industry in recent years; however, ... of industry margins. From 2009 to 2014, industry ... provide coverage for routine eye exams and other ... contact lens and refractive surgery. According to IBISWorld ...
(Date:9/19/2014)... September 19, 2014 Unbound , an ... families in regions of the Philippines being affected by both ... than 1,060 families evacuated to the nearest public schools while ... heavy rain and gusty winds to portions of the northern ... flooding. Some homes filled with more than 10 feet of ...
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... PR News at the Platinum PR and Top Places ... Hyatt in New York City. Camino received honorable mentions ... Shoestring Campaign” — for its work elevating Latina voices ... this incredible organization and be a part of its ...
Breaking Medicine News(10 mins):Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2
... (Nasdaq: GTIV ), a leading provider of comprehensive home,health ... conferences hosted by Oppenheimer & Co., Credit Suisse and,Stephens Inc., ... -- 1:20 p.m. to 1:55 p.m. ET, Monday, November ... & Co. 19th Annual Healthcare Conference in New York. ...
... SGP ) said today that it strongly ... Missouri related to reimbursement by,Missouri,s Medicaid program of ... generics subsidiary, was incorrect.,The company said it will ... all applicable laws and regulations governing reimbursement rules ...
... Technologies Corporation (NASDAQ:DVAX) announced today that it plans to report third quarter ... , ... BERKELEY, Calif. (Business Wire EON) October 30, 2008 -- ... the Oppenheimer 19th Annual Healthcare Conference in New York City on November ...
... Breast Cancer Survivors Learn about the Importance of ... SAN DIEGO, Oct. 30 A large number ... part of the "Know Your,L-Dex" awareness campaign activities ... Houston and Dallas., (Photo: http://www.newscom.com/cgi-bin/prnh/20081030/NY43020 ...
... Conference Call Scheduled Wednesday, November 5, 2008 at 11:00 a.m.,ET ... AFAM ), a leading regional provider of home health ... third quarter,2008 ended September 30, 2008 on Wednesday, November 5, ... the results will begin at 11:00 a.m. ET on,November 5, ...
... International,Inc. (Nasdaq: DATA ), a technology and services ... industry, today announced that,it will host a conference call ... 2008 at 4:30 p.m. ET on Thursday, November 6, ... to dial 412-858-4600 a,few minutes before 4:30 p.m. ET. ...
Cached Medicine News:Health News:Gentiva(R) Health Services to Present at November Investment Conferences Hosted by Oppenheimer, Credit Suisse and Stephens 2Health News:Gentiva(R) Health Services to Present at November Investment Conferences Hosted by Oppenheimer, Credit Suisse and Stephens 3Health News:Schering-Plough to Appeal Jury Decision in Missouri Reimbursement Case 2Health News: Dynavax to Report Third Quarter 2008 Financial Results : -- To Present at Oppenheimer's Healthcare Conference -- 2Health News:'Know Your L-Dex(TM)' (Lymphedema Index) Awareness Campaign Attracts Large Numbers of Breast Cancer Survivors at Komen Race for the Cure(R) Events 2Health News:'Know Your L-Dex(TM)' (Lymphedema Index) Awareness Campaign Attracts Large Numbers of Breast Cancer Survivors at Komen Race for the Cure(R) Events 3Health News:Almost Family, Inc. to Report Third Quarter 2008 Financial Results 2Health News:DATATRAK International Management to Host Conference Call on November 6, 2008 to Discuss Third Quarter and Nine Month Operating Results for 2008 2Health News:DATATRAK International Management to Host Conference Call on November 6, 2008 to Discuss Third Quarter and Nine Month Operating Results for 2008 3
... SC Strep A is a rapid point-of-care ... Strep A antigen in throat swab specimens. ... use no mixing, measuring or working ... cassette format and clearly visible result window ...
... A Twist Rapid Test Device (Throat Swab) is ... a patented design to provide convenience to the ... swab chamber, eliminating the need for test tubes ... exhibits a 93% accuracy compared to plate culture, ...
... Since 1994 the CoaguChek System has been ... needed most, at the point of care. , ... for thousands of patients self-testing when monitoring on ... the user to obtain a result from a ...
... Ovulation Tests are qualitative immunoassays for detecting elevated ... procedure is fast and results are easy to ... is darker than the control band, then ovulation ... If the test band does not appear ...
Medicine Products: